Patent Litigations
1. List of Calquence drug patents
CALQUENCE litigations
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| US10272083 | February, 2023 | Petition Filed | Sandoz Inc. |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10272083 | ASTRAZENECA | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
Jan, 2035
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Oct 31, 2022 |
Drugs and Companies using ACALABRUTINIB MALEATE ingredient
NCE-1 date: 2021-10-31
Market Authorisation Date: 03 August, 2022
Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with chronic lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; Treatment of adult patients with small lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; Treatment of adult patients with previously untreated chronic lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab; Treatment of adult patients with previously untreated small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab; Treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab by administering 100 mg of acalabrutinib twice daily
Dosage: TABLET;ORAL
CALQUENCE family patents
12
United States
3
Taiwan, Province of China
3
IB
2
Argentina
1
Korea, Republic of
1
Australia
1
EA
1
Canada
1
Japan
1
China
1
European Union
2. List of Calquence drug patents
CALQUENCE litigations
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| US10272083 | February, 2023 | Petition Filed | Sandoz Inc. |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10272083 | ASTRAZENECA | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
Jan, 2035
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Nov 21, 2026 |
Drugs and Companies using ACALABRUTINIB ingredient
Market Authorisation Date: 31 October, 2017
Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with small lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; Treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with previously untreated chronic lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab; Treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with chronic lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; Treatment of adult patients with previously untreated small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab
Dosage: CAPSULE;ORAL
CALQUENCE family patents
12
United States
3
Taiwan, Province of China
3
IB
2
Argentina
1
Korea, Republic of
1
Australia
1
EA
1
Canada
1
Japan
1
China
1
European Union
3. List of Mavenclad drug patents
MAVENCLAD litigations
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| US7713947 | January, 2023 | Petition Filed | Hopewell Pharma Ventures, Inc. et al. | |
| US8377903 | January, 2023 | Petition Filed | Hopewell Pharma Ventures, Inc. et al. | |
| US7713947 | October, 2022 | PO preliminary response filed | Merck Serono SA | TWi Pharmaceuticals, Inc. |
| US8377903 | October, 2022 | Submitted | Merck Serono SA | TWi Pharmaceuticals, Inc. |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8377903 | EMD SERONO INC | Cladribine regimen for treating multiple sclerosis |
May, 2026
(3 years from now) | |
| US7713947 | EMD SERONO INC | Cladribine regimen for treating multiple sclerosis |
Oct, 2026
(3 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Mar 29, 2022 |
Drugs and Companies using CLADRIBINE ingredient
Market Authorisation Date: 29 March, 2019
Treatment: Treating rrms or spms with oral cladribine: (i) 2-4 months induction with 1.7 mg/kg - 3.5 mg/kg cladribine; (ii) cladribine-free period of about 8-10 months; (iii) 2-4 months maintenance with about 1.7 mg/kg cladribine; (iv) cladribine-free period; Treating ms with oral cladribine acc. to the steps (i) induction period with about 1.7 mg/kg-3.5 mg/kg cladribine; (iii) maintenance period with about 1.7 mg/kg cladribine
Dosage: TABLET;ORAL
MAVENCLAD family patents
8
European Union
7
Japan
5
Spain
4
United States
3
Portugal
3
Lithuania
3
Slovenia
3
Hungary
3
Poland
3
Denmark
2
Argentina
2
Canada
2
Cyprus
2
Australia
1
Singapore
1
Brazil
1
Croatia
1
Norway
1
Austria
1
Mexico
1
China
1
Korea, Republic of
1
EA
1
South Africa
1
Luxembourg
1
ME
1
Ukraine
1
Israel
1
RS
4. List of Venclexta drug patents
VENCLEXTA litigations
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| US11110087 | October, 2022 | PO preliminary response filed | Genentech, Inc. et al. | Dr. Reddy's Laboratories, Inc. et al. |
| US10993942 | February, 2022 | Trial Instituted | Genentech, Inc. et al. | Dr. Reddy's Laboratories, Inc. et al. |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10993942 | ABBVIE INC | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
Sep, 2033
(10 years from now) | |
| US11110087 | ABBVIE INC | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
Sep, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | May 15, 2026 |
| M (M) | Oct 16, 2023 |
Drugs and Companies using VENETOCLAX ingredient
Market Authorisation Date: 11 April, 2016
Treatment: Treatment of chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) by orally administering venetoclax to an adult according to a dose ramp-up that includes a dose of 50 mg per day for 1 week followed by 100 mg per day for 1 week; Treatment of acute myeloid leukemia (aml) by orally administering venetoclax with azacitidine or decitabine or low-dose cytarabine in adults 75 years or older or having certain comorbidities according to a dose ramp-up including a 100 mg per day dose; Treatment of chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) by orally administering venetoclax to an adult according to a dose ramp-up including a 100 mg per day dose
Dosage: TABLET;ORAL
VENCLEXTA family patents
10
United States
4
Japan
3
China
2
Korea, Republic of
2
European Union
1
Hong Kong
1
New Zealand
1
Russia
1
Canada
1
Mexico
5. List of Trulance drug patents
TRULANCE litigations
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| US7041786 | October, 2022 | Instituted | Salix Pharmaceuticals, Inc. | MSN Laboratories Private Ltd. |
| US9610321 | June, 2022 | Institution Denied | Bausch Health Ireland Limited et al. | Mylan Pharmaceuticals Inc. et al. |
| US9616097 | June, 2022 | Institution Denied | Bausch Health Ireland Limited et al. | Mylan Pharmaceuticals Inc. et al. |
| US9919024 | June, 2022 | Terminated-Denied | Bausch Health Ireland Limited | Mylan Pharmaceuticals Inc. |
| US9925231 | June, 2022 | Institution Denied | Bausch Health Ireland Limited et al. | Mylan Pharmaceuticals Inc. et al. |
| US7041786 | March, 2022 | Trial Instituted | Bausch Health Ireland Limited et al. | Mylan Pharmaceuticals Inc. et al. |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7041786 | SALIX | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Jan, 2028
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9616097 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Aug, 2032
(9 years from now) | |
| US9610321 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(8 years from now) | |
| US9919024 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(8 years from now) | |
| US9925231 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jan 19, 2022 |
Drugs and Companies using PLECANATIDE ingredient
NCE-1 date: 2021-01-19
Market Authorisation Date: 19 January, 2017
Treatment: Chronic idiopathic constipation; Irritable bowel syndrome with constipation
Dosage: TABLET;ORAL
TRULANCE family patents
27
United States
8
Japan
7
European Union
5
Australia
5
Canada
5
China
4
Hong Kong
4
Spain
2
EA
1
Portugal
1
Germany
1
Denmark
1
Cyprus
6. List of Xarelto drug patents
XARELTO litigations
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| US10828310 | September, 2022 | Instituted | Bayer Pharma AG | Teva Pharmaceuticals USA, Inc |
| US10828310 | September, 2022 | Instituted | Bayer Pharma AG | InvaGen Pharmaceuticals, Inc. |
| US10828310 | February, 2022 | Trial Instituted | Bayer Pharma AG et al. | Mylan Pharmaceuticals Inc. et al. |
| US9539218 | May, 2018 | Terminated-Denied | Bayer Intellectual Property GmbH | Mylan Pharmaceuticals Inc. |
| US7157456 | October, 2016 | Terminated-Dismissed | Bayer Intellectual Property GmbH | Mylan Pharmaceuticals Inc |
| US9539218 | January, 2014 | Decision | Frank Misselwitz et al |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7157456 | JANSSEN PHARMS | Substituted oxazolidinones and their use in the field of blood coagulation |
Aug, 2024
(1 year, 5 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9539218 | JANSSEN PHARMS | Prevention and treatment of thromboembolic disorders |
Feb, 2034
(10 years from now) | |
| US10828310 | JANSSEN PHARMS | Reducing the risk of cardiovascular events |
Jan, 2039
(15 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Aug 23, 2024 |
| M (M) | Mar 10, 2023 |
| Pediatric Exclusivity (PED) | Apr 11, 2023 |
Drugs and Companies using RIVAROXABAN ingredient
Market Authorisation Date: 01 July, 2011
Treatment: Treatment of pulmonary embolism with once daily, rapid-release tablet administered for at least five consecutive days; Treatment of deep vein thrombosis with once daily, rapid-release tablet administered for at least five consecutive days; Prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism in patients undergoing knee or hip replacement surgery, with once daily, rapid-release tablet administered for at least five consecutive days; Reduce the risk of stroke in patients with nonvalvular atrial fibrillation with once daily, rapid-release tablet administered for at least five consecutive days; Prophylaxis of venous thromboembolism in acutely ill medical patients at risk for thromboembolic complications not at high risk of bleeding with once daily, rapid-release tablet administered for at least 5 consecutive days; Treatment of dvt and/or pe and reduction in the risk of recurrent dvt and/or pe in pediatric patients (>=50 kg) once daily with rapid-release tablet administered for at least 5 consecutive days after at least 5 days parenteral anticoagulant treatment; After completion of initial treatment lasting at least 6 months, to reduce the risk of recurrence of deep vein thrombosis and/or pulmonary embolism in certain patients with once daily, rapid-release tablet administered for at least 5 consecutive days; Prophylaxis of pe, dvt and/or stroke in pediatric patients (>=50 kg) aged 2 years and older with congenital heart disease after fontan procedure with once daily, rapid-release tablet administered for at least 5 consecutive days; Treatment of dvt and/or pe and reduction in risk of recurrent dvt and/or pe in pediatric patients (30-49.9 kg) once daily with rapid-release tablet administered for at least 5 consecutive days after at least 5 days parenteral anticoagulant treatment; Reduction of risk of cardiovascular death, myocardial infarction, and stroke in patients with cad by administering clinically proven effective amounts that are 2.5 mg rivaroxaban twice daily and 75-100 mg aspirin daily; Reduction of risk of myocardial infarction and ischemic stroke in patients with pad by administering clinically proven effective amounts that are 2.5 mg rivaroxaban twice daily and 75-100 mg aspirin daily
Dosage: TABLET;ORAL
XARELTO family patents
12
United States
6
European Union
5
Norway
4
China
4
Korea, Republic of
3
Portugal
3
Germany
3
Spain
3
Croatia
3
New Zealand
3
Argentina
3
Taiwan, Province of China
3
Hong Kong
3
Japan
3
Slovenia
3
Poland
3
Australia
3
Denmark
2
Turkey
2
Singapore
2
Brazil
2
Dominican Republic
2
Mexico
2
Morocco
2
South Africa
2
Canada
2
Cyprus
2
Hungary
2
Ukraine
2
Cuba
1
El Salvador
1
Malaysia
1
Uruguay
1
Russia
1
Guatemala
1
Colombia
1
Estonia
1
Austria
1
Peru
1
Belgium
1
Honduras
1
Slovakia
1
Lithuania
1
Luxembourg
1
Czech Republic
1
Israel
1
Bulgaria
1
Netherlands
7. List of Idhifa drug patents
IDHIFA litigations
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| US10610125 | August, 2022 | Terminated-Settled | Servier Pharmaceuticals LLC et al. | Rigel Pharmaceuticals, Inc. |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10610125 | CELGENE CORP | Methods and compositions for cell-proliferation-related disorders |
Jun, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Aug 1, 2024 |
Drugs and Companies using ENASIDENIB MESYLATE ingredient
Market Authorisation Date: 01 August, 2017
Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation
Dosage: TABLET;ORAL
IDHIFA family patents
15
United States
3
Japan
2
Australia
2
China
1
Canada
1
Mexico
1
Spain
1
European Union
8. List of Tibsovo drug patents
TIBSOVO litigations
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| US10610125 | August, 2022 | Terminated-Settled | Servier Pharmaceuticals LLC et al. | Rigel Pharmaceuticals, Inc. |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10610125 | SERVIER | Methods and compositions for cell-proliferation-related disorders |
Jun, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 20, 2023 |
| Orphan Drug Exclusivity (ODE) | Aug 25, 2028 |
| New Indication (I) | May 25, 2025 |
Drugs and Companies using IVOSIDENIB ingredient
NCE-1 date: 2022-07-20
Market Authorisation Date: 20 July, 2018
Treatment: A method of treating a cancer characterized by an idh1 mutation where the cancer is relapsed or refractory acute myeloid leukemia (aml) and where the mutant idh1 has the ability to convert alpha-ketoglutarate into 2-hydroxyglutarate (2-hg); A method of treating a cancer characterized by an idh1 mutation where the cancer is newly diagnosed acute myeloid leukemia (aml) and where the mutant idh1 has the ability to convert alpha-ketoglutarate into 2-hydroxyglutarate (2-hg)
Dosage: TABLET;ORAL
TIBSOVO family patents
15
United States
3
Japan
2
Australia
2
China
1
Canada
1
Mexico
1
Spain
1
European Union
9. List of Ozempic drug patents
OZEMPIC litigations
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| US8114833 | March, 2022 | Terminated-Settled | Novo Nordisk A/S | Fresenius Kabi USA, LLC |
| US8114833 | July, 2020 | Terminated-Settled | Novo Nordisk A/S | Pfizer Inc. |
| US8114833 | December, 2019 | Terminated-Settled | Novo Nordisk A/S | Pfizer Inc. |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8114833 | NOVO | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug, 2025
(2 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Jan 16, 2023 |
| New Dosing Schedule (D) | Mar 28, 2025 |
Drugs and Companies using SEMAGLUTIDE ingredient
Market Authorisation Date: 05 December, 2017
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
OZEMPIC family patents
6
United States
4
China
4
Denmark
3
European Union
2
Portugal
2
Spain
2
Japan
2
Hungary
2
Slovenia
2
Poland
1
Turkey
1
Russia
1
Brazil
1
Mexico
1
Korea, Republic of
1
Hong Kong
1
Canada
1
Cyprus
1
Australia
10. List of Saxenda drug patents
SAXENDA litigations
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| US8114833 | March, 2022 | Terminated-Settled | Novo Nordisk A/S | Fresenius Kabi USA, LLC |
| US8114833 | July, 2020 | Terminated-Settled | Novo Nordisk A/S | Pfizer Inc. |
| US8114833 | December, 2019 | Terminated-Settled | Novo Nordisk A/S | Pfizer Inc. |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8114833 | NOVO | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug, 2025
(2 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Dec 4, 2023 |
Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient
Market Authorisation Date: 23 December, 2014
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
SAXENDA family patents
6
United States
4
China
4
Denmark
3
European Union
2
Portugal
2
Spain
2
Japan
2
Hungary
2
Slovenia
2
Poland
1
Turkey
1
Russia
1
Brazil
1
Mexico
1
Korea, Republic of
1
Hong Kong
1
Canada
1
Cyprus
1
Australia
11. List of Victoza drug patents
VICTOZA litigations
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| US8114833 | March, 2022 | Terminated-Settled | Novo Nordisk A/S | Fresenius Kabi USA, LLC |
| US8114833 | July, 2020 | Terminated-Settled | Novo Nordisk A/S | Pfizer Inc. |
| US8114833 | December, 2019 | Terminated-Settled | Novo Nordisk A/S | Pfizer Inc. |
| US9265893 | January, 2014 | Decision | Torben Stroem Hansen et al |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8114833 | NOVO NORDISK INC | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9265893 | NOVO NORDISK INC | Injection button |
Sep, 2032
(9 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Jun 17, 2022 |
| Pediatric Exclusivity (PED) | Dec 17, 2022 |
Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient
Market Authorisation Date: 25 January, 2010
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
VICTOZA family patents
8
United States
6
European Union
5
China
5
Denmark
3
Spain
3
Japan
3
Poland
2
Portugal
2
Russia
2
Brazil
2
Canada
2
Hungary
2
Slovenia
2
Australia
1
Germany
1
Turkey
1
Austria
1
Mexico
1
Korea, Republic of
1
Hong Kong
1
Cyprus
12. List of Lupkynis drug patents
LUPKYNIS litigations
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| US10286036 | February, 2022 | Terminated-Settled | Aurinia Pharmaceuticals Inc. | Sun Pharmaceutical Industries Ltd. et al. |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10286036 | AURINIA | Protocol for treatment of lupus nephritis |
Dec, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jan 22, 2026 |
Drugs and Companies using VOCLOSPORIN ingredient
NCE-1 date: 2025-01-22
Market Authorisation Date: 22 January, 2021
Treatment: Treatment of patients with active lupus nephritis
Dosage: CAPSULE;ORAL
LUPKYNIS family patents
5
United States
2
Japan
1
Korea, Republic of
1
IB
1
Chile
1
Australia
1
Canada
1
Russia
1
South Africa
1
China
1
Brazil
1
European Union
13. List of Vascepa drug patents
VASCEPA litigations
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| US8642077 | November, 2021 | Terminated-Settled | Amarin Pharmaceuticals Ireland Limited | Hikma Pharmaceuticals USA Inc. |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8642077 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Dec 13, 2022 |
Drugs and Companies using ICOSAPENT ETHYL ingredient
Market Authorisation Date: 26 July, 2012
Treatment: Use of vascepa to reduce triglycerides in a mixed dyslipidemia adult patient with elevated triglyceride (tg) levels (>= 150 mg/dl) and on statin therapy
Dosage: CAPSULE;ORAL
VASCEPA family patents
31
United States
3
Singapore
3
Russia
3
Hong Kong
3
European Union
2
Portugal
2
Spain
2
Croatia
2
New Zealand
2
Mexico
2
China
2
Lithuania
2
Slovenia
2
Hungary
2
Denmark
1
Malaysia
1
Brazil
1
Colombia
1
Norway
1
Philippines
1
Korea, Republic of
1
South Africa
1
Canada
1
Cyprus
1
Poland
1
Australia
14. List of Lumify drug patents
LUMIFY litigations
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| US8293742 | November, 2021 | Trial Instituted | Eye Therapies, LLC et al. | Slayback Pharma LLC et al. |
| US9259425 | November, 2021 | Terminated-Settled | Eye Therapies, LLC | Slayback Pharma LLC |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9259425 | BAUSCH AND LOMB INC | Compositions and methods for eye whitening |
Jul, 2030
(7 years from now) | |
| US8293742 | BAUSCH AND LOMB INC | Preferential vasoconstriction compositions and methods of use |
Jul, 2030
(7 years from now) | |
Drugs and Companies using BRIMONIDINE TARTRATE ingredient
Market Authorisation Date: 22 December, 2017
Treatment: Relieves redness of the eye due to minor eye irritations
Dosage: SOLUTION/DROPS;OPHTHALMIC
LUMIFY family patents
42
United States
4
Japan
4
Canada
4
European Union
2
Spain
1
Portugal
1
Slovenia
1
Korea, Republic of
1
Croatia
1
San Marino
1
Poland
1
Cyprus
1
Denmark
1
Russia
1
Mexico
1
Brazil
15. List of Pedmark drug patents
PEDMARK litigations
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| US10596190 | October, 2021 | Trial Instituted | Oregon Health & Science University et al. | Hope Medical Enterprises, Inc. |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10596190 | FENNEC PHARMS INC | Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy |
Jan, 2038
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Sep 20, 2025 |
| Orphan Drug Exclusivity (ODE) | Sep 20, 2029 |
Drugs and Companies using SODIUM THIOSULFATE ingredient
Market Authorisation Date: 20 September, 2022
Treatment: A method of reducing ototoxicity in a human pediatric patient about 5 years of age or under with localized medulloblastoma comprising administering sodium thiosulfate about six hours after administration of cisplatin
Dosage: SOLUTION;INTRAVENOUS
PEDMARK family patents
5
United States
1
Japan
1
Korea, Republic of
1
Israel
1
Singapore
1
Australia
1
Russia
1
Canada
1
China
1
Brazil
1
European Union
16. List of Thiola Ec drug patents
THIOLA EC litigations
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| US11458104 | October, 2021 | Decision | Mission Pharmacal Company |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11458104 | MISSION PHARMACAL CO | NA |
Nov, 2038
(15 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| ODE* (ODE*) | Jun 28, 2026 |
Drugs and Companies using TIOPRONIN ingredient
Market Authorisation Date: 28 June, 2019
Treatment: A method of treating cystinuria by orally administering tiopronin with food to prevent cystine stone formation in adults and pediatric patients with severe homozygous cystinuria
Dosage: TABLET, DELAYED RELEASE;ORAL
17. List of Levulan drug patents
LEVULAN litigations
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| US10357567 | October, 2021 | Terminated-Dismissed | DUSA Pharmaceuticals, Inc. | Biofrontera Inc. |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10357567 | DUSA | Methods for photodynamic therapy |
Jan, 2038
(14 years from now) | |
Drugs and Companies using AMINOLEVULINIC ACID HYDROCHLORIDE ingredient
Market Authorisation Date: 03 December, 1999
Treatment: Treatment of actinic keratoses of upper extremities by photodynamic therapy
Dosage: SOLUTION;TOPICAL
18. List of Austedo drug patents
AUSTEDO litigations
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| US8524733 | September, 2021 | Terminated-Denied | Auspex Pharmaceuticals, Inc. | Apotex Inc. |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8524733 | TEVA BRANDED PHARM | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Apr, 2031
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Apr 3, 2024 |
| M (M) | Jun 24, 2024 |
| Pediatric Exclusivity (PED) | Oct 3, 2024 |
Drugs and Companies using DEUTETRABENAZINE ingredient
Market Authorisation Date: 03 April, 2017
Treatment: NA
Dosage: TABLET;ORAL
AUSTEDO family patents
18
United States
4
Spain
4
European Union
3
Hong Kong
3
Japan
2
China
2
Canada
2
Denmark
1
Portugal
1
Brazil
1
Croatia
1
New Zealand
1
Norway
1
Lithuania
1
Cyprus
1
Slovenia
1
Hungary
1
Poland
1
Australia
19. List of Austedo Xr drug patents
AUSTEDO XR litigations
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| US8524733 | September, 2021 | Terminated-Denied | Auspex Pharmaceuticals, Inc. | Apotex Inc. |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8524733 | TEVA | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Apr, 2031
(8 years from now) | |
Drugs and Companies using DEUTETRABENAZINE ingredient
Market Authorisation Date: 17 February, 2023
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
AUSTEDO XR family patents
18
United States
4
Spain
4
European Union
3
Hong Kong
3
Japan
2
China
2
Canada
2
Denmark
1
Portugal
1
Brazil
1
Croatia
1
New Zealand
1
Norway
1
Lithuania
1
Cyprus
1
Slovenia
1
Hungary
1
Poland
1
Australia
20. List of Chantix drug patents
CHANTIX litigations
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| US6890927 | June, 2021 | Terminated-Settled | Pfizer Inc. | Apotex Inc. |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6890927 | PF PRISM CV | Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
May, 2022
(10 months ago) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M (M) | Feb 22, 2022 |
| Pediatric Exclusivity (PED) | Aug 22, 2022 |
Drugs and Companies using VARENICLINE TARTRATE ingredient
Market Authorisation Date: 10 May, 2006
Treatment: Aid to smoking cessation
Dosage: TABLET;ORAL
CHANTIX family patents
3
United States
2
Ecuador
1
Portugal
1
Germany
1
Malaysia
1
Panama
1
Guatemala
1
Spain
1
Brazil
1
Croatia
1
Costa Rica
1
IB
1
New Zealand
1
AP
1
Dominican Republic
1
Egypt
1
Estonia
1
Norway
1
Austria
1
Argentina
1
Mexico
1
Morocco
1
Peru
1
China
1
Taiwan, Province of China
1
Korea, Republic of
1
Hong Kong
1
EA
1
Tunisia
1
South Africa
1
Slovakia
1
Canada
1
Japan
1
Slovenia
1
Hungary
1
ME
1
Czech Republic
1
Ukraine
1
Iceland
1
Israel
1
OA
1
Yugoslavia
1
Georgia
1
Poland
1
Australia
1
Denmark
1
Bulgaria
1
European Union
21. List of Qelbree drug patents
QELBREE litigations
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| US11324753 | February, 2021 | Decision | Supernus Pharmaceuticals, Inc. |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11324753 | SUPERNUS PHARMS | Method of treatment of attention deficit/hyperactivity disorder (ADHD) |
Sep, 2029
(6 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Apr 2, 2026 |
| New Patient Population (NPP) | Apr 29, 2025 |
Drugs and Companies using VILOXAZINE HYDROCHLORIDE ingredient
NCE-1 date: 2025-04-02
Market Authorisation Date: 02 April, 2021
Treatment: For the treatment of attention deficit hyperactivity disorder (adhd)
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
QELBREE family patents
7
United States
1
Canada
1
Spain
1
European Union
22. List of Tyvaso drug patents
TYVASO litigations
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| US10716793 | January, 2021 | Final Written Decision | United Therapeutics Corporation | Liquidia Technologies, Inc. |
| US9593066 | March, 2020 | Terminated-Denied | United Therapeutics Corp. | Liquidia Technologies, Inc. |
| US9604901 | March, 2020 | FWD Entered | United Therapeutics Corp. | Liquidia Technolgies, Inc. |
| US9339507 | June, 2017 | Terminated-Settled | United Therapeutics Corp. | Watson Laboratories, Inc. |
| US9358240 | June, 2017 | Terminated-Settled | United Therapeutics Corp. | Watson Laboratories, Inc. |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(5 years from now) | |
| US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulin® |
Dec, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9358240 | UNITED THERAP | Treprostinil administration by inhalation |
May, 2028
(5 years from now) | |
| US10716793 | UNITED THERAP | Treprostinil administration by inhalation |
May, 2027
(4 years from now) | |
| US9339507 | UNITED THERAP | Treprostinil administration by inhalation |
Mar, 2028
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Mar 31, 2024 |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 30 July, 2009
Treatment: Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device
Dosage: SOLUTION;INHALATION
TYVASO family patents
23
United States
6
Japan
4
Korea, Republic of
3
China
3
European Union
2
Canada
2
Spain
23. List of Tyvaso Dpi drug patents
TYVASO DPI litigations
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| US10716793 | January, 2021 | Final Written Decision | United Therapeutics Corporation | Liquidia Technologies, Inc. |
| US9593066 | March, 2020 | Terminated-Denied | United Therapeutics Corp. | Liquidia Technologies, Inc. |
| US9604901 | March, 2020 | FWD Entered | United Therapeutics Corp. | Liquidia Technolgies, Inc. |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(5 years from now) | |
| US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulin® |
Dec, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10716793 | UNITED THERAP | Treprostinil administration by inhalation |
May, 2027
(4 years from now) | |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 23 May, 2022
Treatment: Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device
Dosage: POWDER;INHALATION
TYVASO DPI family patents
23
United States
6
Japan
4
Korea, Republic of
3
China
3
European Union
2
Canada
2
Spain
24. List of Cerdelga drug patents
CERDELGA litigations
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| US11458119 | November, 2020 | Decision | Hanlan Liu et al. | |
| US10888547 | April, 2019 | Decision | Genzyme Corporation |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US11458119 | GENZYME CORP | Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
Nov, 2030
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10888547 | GENZYME CORP | Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
Jan, 2031
(7 years from now) | |
Drugs and Companies using ELIGLUSTAT TARTRATE ingredient
Market Authorisation Date: 19 August, 2014
Treatment: Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 poor metabolizers with 84 mg once daily of eliglustat (equivalent to 100 mg of eliglustat tartrate); Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 extensive or intermediate metabolizers with 84 mg twice per day of eliglustat (equivalent to 100 mg of eliglustat tartrate twice per day)
Dosage: CAPSULE;ORAL
CERDELGA family patents
8
United States
6
European Union
5
China
5
Korea, Republic of
5
Japan
4
Portugal
4
Spain
4
Poland
3
Croatia
3
New Zealand
3
Argentina
3
Taiwan, Province of China
3
EA
3
Canada
3
Cyprus
3
Slovenia
3
Australia
3
RS
3
Denmark
2
Singapore
2
Dominican Republic
2
Peru
2
Hong Kong
2
Lithuania
2
Hungary
2
Israel
2
Chile
2
Ecuador
1
Malaysia
1
Guatemala
1
Brazil
1
Costa Rica
1
San Marino
1
Philippines
1
Mexico
1
Morocco
1
Tunisia
1
Nicaragua
1
ME
1
Ukraine
25. List of Cabenuva Kit drug patents
CABENUVA KIT litigations
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| US11389447 | October, 2020 | Decision | JANSSEN SCIENCES IRELAND UC |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11389447 | VIIV HLTHCARE | Aqueous suspensions of TMC278 |
Jun, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jan 21, 2026 |
| New Patient Population (NPP) | Mar 29, 2025 |
| New Dosing Schedule (D) | Jan 31, 2025 |
Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient
NCE-1 date: 2025-01-21
Market Authorisation Date: 21 January, 2021
Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg by monthly administration of rilpivirine suspension as part of combination therapy
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
CABENUVA KIT family patents
5
United States
4
European Union
1
Portugal
1
Singapore
1
Uruguay
1
Spain
1
Jordan
1
Brazil
1
Croatia
1
New Zealand
1
AP
1
Argentina
1
Mexico
1
Peru
1
China
1
Taiwan, Province of China
1
Korea, Republic of
1
EA
1
Lithuania
1
Japan
1
Canada
1
Cyprus
1
Slovenia
1
Hungary
1
Ukraine
1
Israel
1
Poland
1
Chile
1
Australia
1
RS
1
Denmark
26. List of Lutathera drug patents
LUTATHERA litigations
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| US10596276 | October, 2020 | Terminated-Denied | Advanced Accelerator Applications SA | Evergreen Theragnostics, Inc. |
| US10596278 | October, 2020 | Terminated-Denied | Advanced Accelerator Applications SA | Evergreen Theragnostics, Inc. |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10596278 | AAA USA INC | Stable, concentrated radionuclide complex solutions |
Jul, 2038
(15 years from now) | |
| US10596276 | AAA USA INC | Stable, concentrated radionuclide complex solutions |
Jul, 2038
(15 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jan 26, 2023 |
| Orphan Drug Exclusivity (ODE) | Jan 26, 2025 |
Drugs and Companies using LUTETIUM DOTATATE LU-177 ingredient
NCE-1 date: 2022-01-26
Market Authorisation Date: 26 January, 2018
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
LUTATHERA family patents
10
United States
4
Japan
4
European Union
3
IB
3
China
2
Australia
1
Taiwan, Province of China
1
Germany
1
Korea, Republic of
1
Israel
1
Colombia
1
Singapore
1
Canada
1
Argentina
1
Brazil
27. List of Elcys drug patents
ELCYS litigations
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| US10653719 | September, 2020 | Terminated-Denied | Exela Pharma Sciences LLC | Eton Pharmaceuticals, Inc. |
| US10583155 | June, 2020 | Terminated-Denied | Exela Pharma Sciences, LLC | Eton Pharmaceuticals Inc. |
| US10478453 | May, 2020 | Terminated-Denied | Exela Pharma Sciences, LLC | Eton Pharmaceuticals, Inc. |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10653719 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10583155 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10478453 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
Drugs and Companies using CYSTEINE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 April, 2019
Treatment: Method of using l-cysteine in an admixture for treating patients needing parenteral nutrition
Dosage: SOLUTION;INTRAVENOUS
28. List of Nouress drug patents
NOURESS litigations
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| US10653719 | September, 2020 | Terminated-Denied | Exela Pharma Sciences LLC | Eton Pharmaceuticals, Inc. |
| US10583155 | June, 2020 | Terminated-Denied | Exela Pharma Sciences, LLC | Eton Pharmaceuticals Inc. |
| US10478453 | May, 2020 | Terminated-Denied | Exela Pharma Sciences, LLC | Eton Pharmaceuticals, Inc. |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10653719 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10583155 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10478453 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
Drugs and Companies using CYSTEINE HYDROCHLORIDE ingredient
Market Authorisation Date: 13 December, 2019
Treatment: Method of using l-cysteine in an admixture for treating patients needing parenteral nutrition
Dosage: SOLUTION;INTRAVENOUS
29. List of Entresto drug patents
ENTRESTO litigations
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| US8101659 | August, 2020 | Terminated-Denied | Novartis Pharmaceuticals Corporation | Biocon Pharma Limited |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8101659 | NOVARTIS PHARMS CORP | Methods of treatment and pharmaceutical composition |
Jan, 2025
(1 year, 9 months from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M (M) | Feb 16, 2024 |
| Pediatric Exclusivity (PED) | Apr 1, 2023 |
Drugs and Companies using SACUBITRIL; VALSARTAN ingredient
Market Authorisation Date: 07 July, 2015
Treatment: NA
Dosage: TABLET;ORAL
ENTRESTO family patents
7
United States
3
Brazil
2
Norway
2
China
2
Korea, Republic of
2
Japan
2
European Union
1
Portugal
1
Germany
1
Russia
1
Spain
1
Colombia
1
New Zealand
1
Mexico
1
Austria
1
Belgium
1
South Africa
1
Canada
1
Hungary
1
Slovenia
1
Luxembourg
1
Israel
1
Poland
1
Australia
1
Ecuador
1
Denmark
1
Netherlands
30. List of Naproxen Sodium drug patents
NAPROXEN SODIUM litigations
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| US11090280 | July, 2020 | Decision | PATHEON SOFTGELS INC | |
| US9693978 | January, 2018 | Terminated-Denied | Patheon Softgels Inc. | Catalent Pharma Solutions, Inc. |
| US9693979 | January, 2018 | Terminated-Denied | Patheon Softgels Inc. | Catalent Pharma Solutions, Inc. |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9693979 | BIONPHARMA INC | Liquid dosage forms of sodium naproxen |
Mar, 2026
(2 years from now) | |
| US11090280 | BIONPHARMA INC | Liquid dosage forms of sodium naproxen |
Mar, 2026
(2 years from now) | |
| US9693978 | BIONPHARMA INC | Solvent system for enhancing the solubility of pharmaceutical agents |
Mar, 2026
(2 years from now) | |
Drugs and Companies using NAPROXEN SODIUM ingredient
Market Authorisation Date: 17 February, 2006
Treatment: Temporary relief of minor aches and pains; Temporary reduction of fever
Dosage: CAPSULE;ORAL
NAPROXEN SODIUM family patents
9
United States
2
China
2
European Union
1
Portugal
1
Hungary
1
Slovenia
1
Poland
1
Denmark
1
Mexico
1
Lithuania
1
Spain
1
Canada
1
Cyprus
31. List of Janumet drug patents
JANUMET litigations
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| US7326708 | June, 2020 | FWD Entered | Merck Sharp & Dohme Corp. | Sun Pharmaceutical Industries Ltd. |
| US7326708 | June, 2020 | FWD Entered | Merck Sharp & Dohme Corp. | Dr. Reddy's Laboratories, Inc. |
| US7326708 | June, 2020 | Terminated-Settled | Merck Sharp & Dohme Corp. | Teva Pharmaceuticals USA, Inc. |
| US7326708 | October, 2019 | FWD Entered | Merck Sharp & Dohme Corp. | Mylan Pharmaceuticals, Inc. |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7326708 | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(3 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M (M) | Dec 4, 2023 |
| Pediatric Exclusivity (PED) | Jun 4, 2024 |
Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient
Market Authorisation Date: 30 March, 2007
Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor
Dosage: TABLET;ORAL
JANUMET family patents
3
United States
2
Argentina
2
Korea, Republic of
1
Portugal
1
Germany
1
Malaysia
1
Spain
1
Jordan
1
Brazil
1
Croatia
1
Costa Rica
1
Colombia
1
New Zealand
1
Dominican Republic
1
Norway
1
Austria
1
Mexico
1
Morocco
1
Peru
1
China
1
Taiwan, Province of China
1
Hong Kong
1
Tunisia
1
EA
1
South Africa
1
Canada
1
Japan
1
Cyprus
1
Slovenia
1
ME
1
Yugoslavia
1
Ukraine
1
Israel
1
Iceland
1
Georgia
1
Poland
1
Australia
1
Ecuador
1
Denmark
1
European Union
32. List of Janumet Xr drug patents
JANUMET XR litigations
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| US7326708 | June, 2020 | FWD Entered | Merck Sharp & Dohme Corp. | Sun Pharmaceutical Industries Ltd. |
| US7326708 | June, 2020 | FWD Entered | Merck Sharp & Dohme Corp. | Dr. Reddy's Laboratories, Inc. |
| US7326708 | June, 2020 | Terminated-Settled | Merck Sharp & Dohme Corp. | Teva Pharmaceuticals USA, Inc. |
| US7326708 | October, 2019 | FWD Entered | Merck Sharp & Dohme Corp. | Mylan Pharmaceuticals, Inc. |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7326708 | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(3 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M (M) | Dec 4, 2023 |
| Pediatric Exclusivity (PED) | Jun 4, 2024 |
Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient
Market Authorisation Date: 02 February, 2012
Treatment: Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and metformin hcl extended release is appropriate
Dosage: TABLET, EXTENDED RELEASE;ORAL
JANUMET XR family patents
3
United States
2
Argentina
2
Korea, Republic of
1
Portugal
1
Germany
1
Malaysia
1
Spain
1
Jordan
1
Brazil
1
Croatia
1
Costa Rica
1
Colombia
1
New Zealand
1
Dominican Republic
1
Norway
1
Austria
1
Mexico
1
Morocco
1
Peru
1
China
1
Taiwan, Province of China
1
Hong Kong
1
Tunisia
1
EA
1
South Africa
1
Canada
1
Japan
1
Cyprus
1
Slovenia
1
ME
1
Yugoslavia
1
Ukraine
1
Israel
1
Iceland
1
Georgia
1
Poland
1
Australia
1
Ecuador
1
Denmark
1
European Union
33. List of Januvia drug patents
JANUVIA litigations
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| US7326708 | June, 2020 | FWD Entered | Merck Sharp & Dohme Corp. | Sun Pharmaceutical Industries Ltd. |
| US7326708 | June, 2020 | FWD Entered | Merck Sharp & Dohme Corp. | Dr. Reddy's Laboratories, Inc. |
| US7326708 | June, 2020 | Terminated-Settled | Merck Sharp & Dohme Corp. | Teva Pharmaceuticals USA, Inc. |
| US7326708 | October, 2019 | FWD Entered | Merck Sharp & Dohme Corp. | Mylan Pharmaceuticals, Inc. |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7326708 | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(3 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M (M) | Dec 4, 2023 |
| Pediatric Exclusivity (PED) | Feb 12, 2023 |
Drugs and Companies using SITAGLIPTIN PHOSPHATE ingredient
Market Authorisation Date: 16 October, 2006
Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor
Dosage: TABLET;ORAL
JANUVIA family patents
3
United States
2
Argentina
2
Korea, Republic of
1
Portugal
1
Germany
1
Malaysia
1
Spain
1
Jordan
1
Brazil
1
Croatia
1
Costa Rica
1
Colombia
1
New Zealand
1
Dominican Republic
1
Norway
1
Austria
1
Mexico
1
Morocco
1
Peru
1
China
1
Taiwan, Province of China
1
Hong Kong
1
Tunisia
1
EA
1
South Africa
1
Canada
1
Japan
1
Cyprus
1
Slovenia
1
ME
1
Yugoslavia
1
Ukraine
1
Israel
1
Iceland
1
Georgia
1
Poland
1
Australia
1
Ecuador
1
Denmark
1
European Union
34. List of Juvisync drug patents
JUVISYNC litigations
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| US7326708 | June, 2020 | FWD Entered | Merck Sharp & Dohme Corp. | Sun Pharmaceutical Industries Ltd. |
| US7326708 | June, 2020 | FWD Entered | Merck Sharp & Dohme Corp. | Dr. Reddy's Laboratories, Inc. |
| US7326708 | June, 2020 | Terminated-Settled | Merck Sharp & Dohme Corp. | Teva Pharmaceuticals USA, Inc. |
| US7326708 | October, 2019 | FWD Entered | Merck Sharp & Dohme Corp. | Mylan Pharmaceuticals, Inc. |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7326708 | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Apr, 2026
(3 years from now) | |
Drugs and Companies using SIMVASTATIN; SITAGLIPTIN PHOSPHATE ingredient
Market Authorisation Date: 07 October, 2011
Treatment: Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and simvastatin is appropriate
Dosage: TABLET;ORAL
JUVISYNC family patents
3
United States
2
Argentina
2
Korea, Republic of
1
Portugal
1
Germany
1
Malaysia
1
Spain
1
Jordan
1
Brazil
1
Croatia
1
Costa Rica
1
Colombia
1
New Zealand
1
Dominican Republic
1
Norway
1
Austria
1
Mexico
1
Morocco
1
Peru
1
China
1
Taiwan, Province of China
1
Hong Kong
1
Tunisia
1
EA
1
South Africa
1
Canada
1
Japan
1
Cyprus
1
Slovenia
1
ME
1
Yugoslavia
1
Ukraine
1
Israel
1
Iceland
1
Georgia
1
Poland
1
Australia
1
Ecuador
1
Denmark
1
European Union
35. List of Steglujan drug patents
STEGLUJAN litigations
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| US7326708 | June, 2020 | FWD Entered | Merck Sharp & Dohme Corp. | Sun Pharmaceutical Industries Ltd. |
| US7326708 | June, 2020 | FWD Entered | Merck Sharp & Dohme Corp. | Dr. Reddy's Laboratories, Inc. |
| US7326708 | June, 2020 | Terminated-Settled | Merck Sharp & Dohme Corp. | Teva Pharmaceuticals USA, Inc. |
| US7326708 | October, 2019 | FWD Entered | Merck Sharp & Dohme Corp. | Mylan Pharmaceuticals, Inc. |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7326708 | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(3 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M (M) | Sep 17, 2024 |
Drugs and Companies using ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE ingredient
Market Authorisation Date: 19 December, 2017
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Dosage: TABLET;ORAL
STEGLUJAN family patents
3
United States